Nihon Chouzai Co Ltd
TSE:3341
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
Market Cap | EV/EBITDA | ||||
---|---|---|---|---|---|
JP |
Nihon Chouzai Co Ltd
TSE:3341
|
42.4B JPY | 4 | ||
ZA |
C
|
Clicks Group Ltd
JSE:CLS
|
75.2B Zac | 0 | |
ZA |
D
|
Dis-Chem Pharmacies Ltd
JSE:DCP
|
28.9B Zac | 0 | |
US |
Walgreens Boots Alliance Inc
NASDAQ:WBA
|
15.8B USD | 5.4 | ||
BR |
Raia Drogasil SA
BOVESPA:RADL3
|
46.4B BRL | 13.3 | ||
CN |
Yifeng Pharmacy Chain Co Ltd
SSE:603939
|
46.5B CNY | 23.8 | ||
JP |
MatsukiyoCocokara & Co
TSE:3088
|
929.8B JPY | 9.1 | ||
SA |
Al Nahdi Medical Company SCJSC
SAU:4164
|
17.5B SAR | 11 | ||
MX |
Corporativo Fragua SAB de CV
BMV:FRAGUAB
|
78.3B MXN | 7.4 | ||
JP |
Cosmos Pharmaceutical Corp
TSE:3349
|
560B JPY | 11 | ||
CN |
D
|
DaShenLin Pharmaceutical Group Co Ltd
SSE:603233
|
25.6B CNY | 15.2 |
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.